A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was ...

A team from the Montreal Clinical Research Institute has identified a protein that could play a role in the spread of breast ...

Discover 8 key causes of bloody cough from infections to lung conditions. Learn when coughing blood needs medical attention ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that it will present latest clinical ...

Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

In patients with nonirradiated brain metastases at baseline (n = 30), the confirmed CNS ORR by BICR per CNS RECIST was 33.3% (95% CI, 17.3 to 52.8). The safety profile (National Cancer Institute ...

Common cancer symptoms like lumps are rarely associated with a Stage 0 cancer diagnosis – meaning they're almost exclusively ...

THE College of Science of the University of the Philippines Diliman on May 26 said that its biologists have developed a ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...